.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,765,117

« Back to Dashboard

Claims for Patent: 6,765,117

Title: Process for stereoselective synthesis of prostacyclin derivatives
Abstract:An improved method is described for making 9-deoxy-PGF.sub.1 -type compounds. In contrast to the prior art, the method is stereoselective and requires fewer steps than the known methods for making these compounds. The invention also relates to novel intermediates prepared during the synthesis of the 9-deoxy-PGF.sub.1 -type compounds.
Inventor(s): Moriarty; Robert M. (Oak Park, IL), Penmasta; Raju (Bolingbrook, IL), Guo; Liang (Chicago, IL), Rao; Munagala S. (Westmont, IL), Staszewski; James P. (Naperville, IL)
Assignee: United Therapeutic Corporation (Washington, DC)
Application Number:10/184,907
Patent Claims: 1. A stereoselectively produced isomeric compound according to the following formula: ##STR26## that is produced by a process for making 9-deoxy-PGF.sub.1 -type compounds, the process comprising cyclizing a starting compound of the formula: ##STR27## into a compound of the following formula: ##STR28## by intramolecular cyclization of the enyne, wherein Z is O, S, CH.sub.2, or NR.sub.8 in which R.sub.8 is H, alkyl or aryl; X is H, CN, OR.sub.9, or COOR.sub.9 in which R.sub.9 is H, alkyl, a pharmacologically acceptable cation, THP or TBDMS; wherein n is 0, 1, 2, or 3; wherein Y.sub.1 is trans-CH.dbd.CH--, cis-CH.dbd.CH--, CH.sub.2 (CH.sub.2).sub.m -, or --C.ident.C--; m is 1,2, or 3; wherein R.sub.1 is an alcohol protecting group; wherein R.sub.7 is (1) --C.sub.2 H.sub.2p --CH.sub.3, wherein p is an integer from one to 5, inclusive, (2) phenoxy optionally substituted by one, two or three chloro, fluoro, trifluoromethyl, (C.sub.1 -C.sub.3)alkyl, or (C.sub.1 -C.sub.3)alkoxy, with the proviso that not more than two substituents are other than alkyl, with the proviso that R.sub.7 is phenoxy or substituted phenoxy, only when R.sub.3 and R.sub.4 are hydrogen or methyl, being the same or different, (3) phenyl, benzyl, phenylethyl, or phenylpropyl optionally substituted on the aromatic ring by one, two or three chloro, fluoro, trifluoromethyl, (C.sub.1 -C.sub.3)alkyl, or (C.sub.1 -C.sub.3)alkoxy, with the proviso that not more than two substituents are other than alkyl, (4) cis-CH.dbd.CH--CH.sub.2 --CH.sub.3, (5) --(CH.sub.2).sub.2 --CH(OH)--CH.sub.3, or (6) --(CH.sub.2).sub.3 --CH.dbd.C(CH.sub.3).sub.2 ; wherein --C(L.sub.1)--R.sub.7 taken together is (1) (C.sub.4 -C.sub.7)cycloalkyl optionally substituted by one to 3 (C.sub.1 -C.sub.5) alkyl; (2) 2-(2-furyl)ethyl, (3) 2-(3-thienyl)ethoxy, or (4) 3-thienyloxymethyl; wherein M.sub.1 is .alpha.-OH:.beta.-R.sub.5 or .alpha.-R.sub.5 :.beta.-OH or .alpha.-OR.sub.1 :.beta.-R.sub.5 or .alpha.-R.sub.5 :.beta.-OR.sub.1, wherein R.sub.5 is hydrogen or methyl and R.sub.1 is an alcohol protecting group; and wherein L.sub.1 is .alpha.-R.sub.3 :.beta.-R.sub.4, .alpha.-R.sub.4 :.beta.-R.sub.3, or a mixture of .alpha.-R.sub.3 :.beta.-R.sub.4 and .alpha.-R.sub.4 :.beta.-R.sub.3, wherein R.sub.3 and R.sub.4 are hydrogen, methyl, or fluoro, being the same or different, with the proviso that one of R.sub.3 and R.sub.4 is fluoro only when the other is hydrogen or fluoro.

2. The stereoselectively produced isomeric compound of claim 1, wherein Z is O, n is 1, X is COOH, Y.sub.1 is -CH.sub.2 CH.sub.2 - M.sub.1 is .alpha.-OH:.beta.-R.sub.5, wherein R.sub.5 is hydrogen, L.sub.1 is .alpha.-R.sub.3 :.beta.-R.sub.4, wherein R.sub.3 and R.sub.4 are hydrogen and R.sub.7 is butyl.

3. A steroselectively produced isomeric compound according to the following formula: ##STR29## that is produced by a process for making 9-deoxy-PFG.sub.1 -type compounds, the process comprising cyclizing a starting compound of the formula: ##STR30## into a compound of the following formula: ##STR31## by intramolecular cyclization of the enyne, wherein Z is O, S, CH.sub.2, or NR.sub.8 in which R.sub.8 is H, alkyl or aryl; X is H, CN, OR.sub.9, or COOR.sub.9 in which R.sub.9 is H; wherein n is 0, 1, 2, or 3; wherein Y.sub.1 is trans-CH=CH-, cis-CH=CH-, -CH.sub.2 (CH.sub.2).sub.m -, or -C=C-; m is 1,2, or 3; wherein R.sub.1 is an alcohol protecting group; wherein R.sub.7 is (5) -C.sub.p H.sub.2p -CH.sub.3, wherein p is an integer from one to 5, inclusive, (6) phenoxy optionally substituted by one, two or three chloro, fluoro, trifluoromethyl, (C.sub.1 -C.sub.3)alkyl, or (C.sub.1 -C.sub.3)alkoxy, with the proviso that not more than two substituents are other than alkyl, with the proviso that R.sub.7 is phenoxy or substituted phenoxy, only when R.sub.3 and R.sub.4 are lydrogen or methyl, being the same or different, (7) phenyl, bnezyl, phenylethyl, or phenylpropyl optionally substituted on the aromatic ring by one, two or three chloro, fluoro, trifluoromethyl, (C.sub.1 -C.sub.3)alkyl, or (C.sub.1 -C.sub.3)alkoyx, with the proviso that not more than two substituents are other than alkyl, (8) cis-CH=CH-CH.sub.2 -CH.sub.3, (9) -(CH.sub.2).sub.2 -CH(OH)-CH.sub.3, or (10) -(CH.sub.2).sub.3 -CH=C(CH.sub.3).sub.2 ; wherein -C(L.sub.1)-R.sub.7 taken together is (11) (C.sub.6 -C.sub.7)cycloalkyl optionally substituted by one to 3 (C.sub.1 -C.sub.5) alkyl; (12) 2-(2-furyl)ethyl, (13) 2-(3-thienyl)ethoxy, or (14) 3-thienyloxymethyl; wherein M.sub.1 is .alpha.-OH:.beta.-R.sub.5 or .alpha.-R.sub.5 :.beta.-OH or .alpha.-OR.sub.1 :.beta.-R.sub.5 or .alpha.-R.sub.5 :.beta.-OR.sub.1, wherein R.sub.5 is hydrogen or methyl and R.sub.1 is an alcohol protecting group; and wherein L.sub.1 is .alpha.-R.sub.3 :.beta.-R.sub.4, .alpha.-R.sub.4 :.beta.-R.sub.3, or a mixture of .alpha.-R.sub.3 :.beta.-R.sub.4 and .alpha.-R.sub.4 :.beta.-R.sub.3, wherein R.sub.3 and R.sub.4 are hydrogen, methyl, or fluoro, being the same or different, with the proviso that one of R.sub.3 and R.sub.4 is fluoro only when the other is hydrogen or fluoro.

4. A steroselectively produced isomeric compound in pharmacologically acceptable salt form according to the following formula: ##STR32## that is produced by process for making 9-deoxy-PGF.sub.1 -type compounds, the process comprising cyclizing a starting compound of the formula: ##STR33## into a compound of the following formula: ##STR34## by intramolecular cyclization of the enyne, wherein Z is O, S, CH.sub.2, or NR.sub.8 in which R.sub.8 is H, alkyl or aryl; X is H, CN, OR.sub.9, or COOR.sub.9 in which R.sub.9 is a pharmacologically acceptable cation; wherein n is 0, 1, 2, or 3; wherein Y.sub.1 is trans-CH=CH-, cis-CH=CH-, -CH.sub.2 (CH.sub.2).sub.m -, or -C=C-; m is 1,2, or 3; wherein R.sub.1 is an alcohol protecting group; wherein R.sub.7 is (1) -C.sub.p H.sub.2p -CH.sub.3, wherein p is an integer from one to 5, inclusive, (2) phenoxy optionally substituted by one, two or three chloro, fluoro, trifluoromethyl, (C.sub.1 -C.sub.3)alkyl, or (C.sub.1 -C.sub.3)alkoxy, with the proviso that not more than two substituents are other than alkyl, with the proviso that R.sub.7 is phenoxy or substituted phenoxy, only when R.sub.3 and R.sub.4 are hydrogen or methyl, being the same or different, (3) phenyl ,benzyl, phenylethyl, or phenylpropyl optionally substituted on the aromatic ring by one, tow or three chloro, fluoro, tribluoromethyl, (C.sub.1 -C.sub.3)alkyl, or (C.sub.1 -C.sub.3)alkoyx, with the proviso that not more than two substituents are other than alkyl, (4) cis-CH=CH-CH.sub.2 -CH.sub.3, (5) -(CH.sub.2).sub.2 -CH(OH)-CH.sub.3, or (6) -(CH.sub.2).sub.3 -CH=C(CH.sub.3).sub.2 ; wherein -C(L.sub.1)-R.sub.7 taken together is (1) (C.sub.4 -C.sub.7)cycloalkyl optionally substituted by one to 3 (C.sub.1 -C.sub.5) alkyl; (2) 2-(2-furyl)ethyl, (3) 2-(3-thienyl)ethoxy, or (4) 3-thienyloxymethyl; wherein M.sub.1 is .alpha.-OH:.beta.-R.sub.4 or .alpha.-R.sub.5 :.beta.-OH or .alpha.-OR.sub.1 :.beta.-R.sub.5 or .alpha.-R.sub.5 :.beta.-OR.sub.1, wherein R.sub.5 is hydrogen or methyl and R.sub.1 is an alcohol protecting group; and wherein L.sub.1 is .alpha.-R.sub.3 :.beta.-R.sub.4, .alpha.-R.sub.4 :.beta.-R.sub.3, or a mixture of .alpha.-R.sub.3 :.beta.-R.sub.4 and .alpha.-R.sub.4 :.beta.-R.sub.3, wherein R.sub.3 and R.sub.4 are kydrogen, methyl, or fluoro, being the same or different, with the proviso that one of R.sub.3 and R.sub.4 is fluoro only when the other is hydrogen or fluoro.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc